Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Tripeptides – e.g. – tripeptide thyroliberin – etc.
Reexamination Certificate
2005-05-26
2009-08-18
Kosar, Andrew D (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Tripeptides, e.g., tripeptide thyroliberin , etc.
C530S326000, C530S327000, C530S328000, C530S329000, C530S330000, C530S333000, C530S345000, C514S013800, C514S014800, C514S015800, C514S016700, C514S017400, C514S018700
Reexamination Certificate
active
07576175
ABSTRACT:
The present invention provides α4β1integrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino acids, wherein at least one amino acid is an unnatural amino acid or a D-amino acid, and wherein n is an integer of from 3 to 20. Methods are provided for administering the ligands for treating cancer, inflammatory diseases, and autoimmune diseases. Also provided are methods for administering the ligands for imaging a tumor, organ, or tissue in a subject.
REFERENCES:
patent: 6248713 (2001-06-01), Lin et al.
patent: WO 9703094 (1997-01-01), None
patent: WO 9842656 (1998-10-01), None
L.L. Chen et al. Biochemistry (1998) 37(24), pp. 8743-8753.
Aina et al., “Therapeutic Cancer Targeting Peptides. Biopolymers,”Peptide Science, 66:184-199, (2002).
Barnes et al., “Recent developments in the encoding and deconvolution of combinatorial libraries,”Curr. Opin. Chem. Biol. 4:346-350 (2000).
Chait et al., “Protein ladder sequencing,”Science262:89-92 (1993).
Chen et al., “Identification of Ligand Binding Sites on Integrin 41 through Chemical Cross-Linking,”Biochem., 37:8743-8753 (1998).
Chen et al., “One bead-one compound combinatorial peptide library: different types of screening,”Methods Enzymol. 267:211-219 (1996).
Coiffier et al., “Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study,”Blood, 92(6):1927-1932 (1998).
Czarnik, “Encoding methods for combinatorial chemistry,”Curr Opin. Chem. Biol. 1: 60-66 (1997).
Damiano et al., “Integrin-mediated drug resistance in multiple myeloma,”Leuk. Lymphoma. 38: 71-81 (2000).
De La Fuente et al., “Fibronectin interaction with 4β1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax,”Leukemia13:266-274 (1999).
Foon et al., “Are Solid Tumor Anti-Idiotype Vaccines Ready for Prime Time?”Clin. Cancer Res. 7:1112-1115 (2001).
Klominek et al., “Differential motile response of human malignant mesothelioma cells to fibronectin, laminin and collagen type IV: The role of 1 integrins,”Int. J. Cancer, 72:1034-1044 (1997).
Hemler, “VLA proteins in the integrin family: structures, functions, and their role on leukocytes,”Ann. Rev. Immunol., 8:365 (1990).
Holzmann et al., “4 integrins and tumor metastasis,”Curr. Top. Microbiol. Immunol., 231:125-141 (1998).
Hood et al., “Role of integrins in. cell invasion and migration,”Nat. Rev. Cancer, 2:91-100 (2002).
Hynes, “Integrins: bidirectional, allosteric signaling machines,”Cell, 110:673-687 (2002).
Hynes, “Integrins: versatility, modulation and signaling in cell adhesion,”Cell, 69:11-25 (1992).
Jin et al., “Integrins: roles in cancer development and as treatment targets,”Brit. J. Cancer, 90:561-565 (2004).
Kwekkeboom et al., “Peptide Receptor Imaging and Therapy,”J. Nucl. Med. 41:1704-1713 (2000).
Okarvi, “Peptide-based radiopharmaceuticals: Future tools for diagnostic imaging of cancers and other diseases,”Med. Res. Rev. 24(3):357-359 (2004).
Lam et al., “The “One-Bead-One-Compound” Combinatorial Library Method,”Chem. Rev. 97(2):411-448 (1997).
Lam et al., “A new type of synthetic peptide library for identifying ligand-binding activity,”Nature, 354:82-84 (1991).
Lin et al., “Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents ,”Curr Opin. Chem. Biol. 2(4):453-457 (1998).
Lin et al., “Selective, Tight-binding Inhibitors of Integrin Alpha-4-beta-1 that Inhibit Allergic Airway Responses,”J. Med. Chem., 42:920-934 (1999).
Liu et al., “A novel peptide-based encoding system for ‘one-bead one-compound’ and small molecule combinational libraries,”J. Am. Chem. Soc. , 124:7678-7680 (2002).
Lowman et al., “Baceriophage display and discovery of peptide leads for drug development,”Annu. Rev. Biophys. Biomol. Struct., 26:401-424 (1997).
Marco et al., “Alpha 4 integrin increases anoikis of human osteosarcoma cells.,”J. Cell. Biochem. 88, 1038-1047 (2003).
Park et al., “The use of one-bead one-compound combinatorial library method to identify peptide ligands for 4β1 integrin receptor in non-Hodgkin's lymphoma,”Lett. Pept. Sci., 8:171-178 (2002).
Pasqualini et al., “Organ targeting In vivo using phage display peptide libraries,”Nature380:364-366 (1996).
Shimaoka et al., “Conformational Regulation Of Integrin Structure And Function,”Annu. Rev. Biophys. Biomol. Struct. 31:485-516 (2002).
Song et al., “A novel and rapid encoding method based on mass spectrometry for “one-bead-one-compound” small molecule combinatorial libraries,”J. Am. Chem. Soc. 125(20):6180-6188 (2003).
Till et al., “The chemokine receptor CCR7 and 4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes,”Blood99(8):2977 (2002).
Vincent et al., “Integrin function in chronic lymphocytic leukemia,”Blood87(11):4780-4788(1996).
Wang et al., “Encoding method for OBOC small molecule libraries using a biphasic approach for ladder-synthesis of coding tags,”J. Am. Chem. Soc. 126:5740-5749 (2004).
Youngquist et al., “Generation and screening of combinatorial peptide libraries designed for rapid sequencing by mass-spectrometry,”J. Am. Chem. Soc. 117, 3900-3906 (1995).
Yusuf-Makagiansar et al., “Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases,”Med. Res. Reviews, 22:146-167 (2002).
Lam Kit S.
Liu Ruiwu
Peng Li
Kosar Andrew D
The Regents of the University of California
Townsend and Townsend / and Crew LLP
LandOfFree
Alpha-4 beta-1 integrin ligands for imaging and therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alpha-4 beta-1 integrin ligands for imaging and therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha-4 beta-1 integrin ligands for imaging and therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4133971